This Week in Endocrinology — Jun 13, 2026

Welcome to This Week in Endocrinology. This week we're covering 9 notable papers spanning major advances in diabetes care, new perspectives on metabolic disease, and key updates in reproductive endocrinology. Let's dive in.

We begin with diabetes management, where a major new trial is making headlines. Published in The Lancet, the phase 3 TRANSCEND-T2D-1 trial evaluated retatrutide, a novel triple agonist targeting GIP, GLP-1, and glucagon receptors [7]. The study enrolled over 500 adults with type 2 diabetes inadequately controlled by diet and exercise alone. After 40 weeks, retatrutide demonstrated significant, dose-dependent improvements in both glycemic control and body weight. Compared to placebo, the highest dose of 12 mg reduced HbA1c by a mean of 1.12%, bringing the average HbA1c down by nearly two full percentage points from baseline. The effects on weight were equally impressive, with the 12 mg dose leading to a mean body weight reduction of over 15%. The side effect profile was consistent with the GLP-1 agonist class, consisting mainly of mild to moderate gastrointestinal events that subsided over time, with low discontinuation rates. While new agents are changing the outpatient landscape, a study in Diabetologia reminds us of persistent challenges in the hospital setting [8]. This single-center observational study used continuous glucose monitors to track what happens between a point-of-care fingerstick glucose measurement and the administration of correctional insulin. Researchers found a mean delay of over 50 minutes. During this time, glucose levels often changed enough that, had an updated value been available, the correctional insulin dose would have been different in over 28% of cases. This highlights a significant and common source of potential dosing errors and suggests a clear role for real-time CGM to optimize inpatient insulin therapy. Shifting focus to Type 1 diabetes, another paper in Diabetologia explored new ways to track disease risk at the molecular level [9]. Researchers identified a signature of five microRNAs found in plasma extracellular vesicles that could differentiate individuals with autoantibody positivity or recent-onset type 1 diabetes from controls with good sensitivity and specificity. One of these, miR-155, was also found to be altered in pancreatic tissue from donors with type 1 diabetes. In a preclinical proof-of-concept, targeted inhibition of this specific microRNA in the beta cells of NOD mice improved glucose tolerance and reduced insulitis, suggesting these biomarkers may also represent future therapeutic targets.

This week also brought several papers that broaden our understanding of metabolic disease, from the cellular level to global public health. A comprehensive review in Nature Reviews Endocrinology provides a state-of-the-art overview of adipose tissue, framing it not just as a storage depot but as a critical humoral and neuronal hub in metabolic regulation [1]. The authors detail the dual communication pathways—including secreted hormones and lipids as well as direct neural circuits—that allow fat tissue to coordinate systemic energy balance. This integrated view is reinforced by a broad review in The Lancet on cardiometabolic multiple long-term conditions, which emphasizes the shared mechanisms of insulin resistance, adiposity, and chronic inflammation that link these diseases together across the life course [6]. This mechanistic perspective is informing new drug design, as shown in a paper in Nature that introduces a first-in-class pulsatile FXR agonist, linafexor, for bile-acid-related liver diseases [3]. Many drugs that provide continuous activation of nuclear receptors run into problems with toxicity and reduced efficacy. To solve this, linafexor was engineered for rapid systemic clearance, allowing it to provide pulsatile receptor activation that mirrors the body's natural bile acid dynamics. This approach preserved cyclic signaling and avoided toxicity in preclinical models, and in phase 1 clinical studies, once-daily dosing produced transient pathway engagement without treatment-related adverse events. Zooming out to population health, a 34-year observational study in The Lancet Global Health analyzed the worldwide adoption of sugar-sweetened beverage taxes [5]. The analysis, covering 183 countries, found that 64 countries have implemented such taxes, with adoption accelerating over time. Interestingly, the key predictors of a country implementing a tax were not baseline sugar-sweetened beverage intake, but rather higher national diabetes and obesity prevalence, and higher gross domestic product. This suggests that policy adoption is often a response to an existing health and economic context, rather than a purely preventative measure based on consumption patterns.

Finally, we turn to reproductive endocrinology, with two papers clarifying the pathophysiology of common and challenging conditions. For clinicians managing adolescents with Klinefelter syndrome, a study in Clinical Endocrinology offers a more precise timeline of testicular failure during puberty [2]. The retrospective study of 57 patients found that Sertoli cell dysfunction, marked by rising FSH and declining inhibin B, appears within the first 12 months of pubertal onset. In contrast, Leydig cell dysfunction, with elevated LH, emerges much later—typically after 36 months. By the completion of puberty, nearly all patients had Sertoli cell insufficiency and 80% had Leydig cell insufficiency. The clinical implication is clear: discussions around fertility preservation strategies should be timed according to pubertal stage, not just chronological age, with the window of opportunity beginning to close early in puberty. And for another complex condition, a review in Endocrine Reviews synthesizes the mechanisms behind endometriosis-associated pain [4]. The authors emphasize a key clinical observation: pain severity often correlates poorly with the burden of endometriotic lesions. The review builds a case that the pain arises from a convergence of endocrine dysregulation, immune activation, and maladaptive neural plasticity, with estrogen dominance and progesterone resistance acting as central drivers. This framework supports a move beyond a purely lesion-focused approach to treatment, toward strategies that target the underlying neuroimmune and endocrine pathways that perpetuate pain.

If you only have time for one paper this week, make it the TRANSCEND-T2D-1 trial on retatrutide in The Lancet [7]. The impressive glycemic and weight-lowering effects of this triple agonist as a monotherapy signal a significant new option on the horizon for patients with early type 2 diabetes.

Here are the key takeaways from this week in Endocrinology: First, the triple GIP, GLP-1, and glucagon receptor agonist retatrutide shows robust efficacy for both glycemic control and weight loss in early type 2 diabetes, with HbA1c reductions nearing two percent and weight loss over 15 percent at the highest dose. Second, in the hospital, significant time delays between glucose checks and correctional insulin administration are common and may lead to incorrect dosing in over a quarter of cases, highlighting a potential role for real-time continuous glucose monitoring. Third, in Klinefelter syndrome, Sertoli cell failure begins within a year of pubertal onset, well before Leydig cell dysfunction. This timeline should guide time-sensitive discussions about fertility preservation based on pubertal stage. Fourth, a new 'pulsatile' FXR agonist, linafexor, shows promise for metabolic liver diseases by mimicking natural signaling cycles to improve safety, representing a novel concept in drug design. And finally, global adoption of sugar-sweetened beverage taxes is accelerating and is driven more by a country's economic capacity and existing disease burden than by its baseline beverage consumption.

That's your roundup for This Week in Endocrinology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.